Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform

BACKGROUND: The MORPHEUS platform comprises multiple open-label, randomized, phase Ib/II trials designed to identify early efficacy and safety signals of treatment combinations across cancers. Atezolizumab (anti-programmed cell death 1 ligand 1 [PD-L1]) was evaluated in combination with PEGylated re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Andrew H, Kim, Kyu-Pyo, Siveke, Jens T, Lopez, Charles D, Lacy, Jill, O’Reilly, Eileen M, Macarulla, Teresa, Manji, Gulam A, Lee, Jeeyun, Ajani, Jaffer, Alsina Maqueda, Maria, Rha, Sun-Young, Lau, Janet, Al-Sakaff, Nedal, Allen, Simon, Lu, Danny, Shemesh, Colby S, Gan, Xinxin, Cha, Edward, Oh, Do-Youn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243783/
https://www.ncbi.nlm.nih.gov/pubmed/36940261
http://dx.doi.org/10.1093/oncolo/oyad022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243783/
https://www.ncbi.nlm.nih.gov/pubmed/36940261
http://dx.doi.org/10.1093/oncolo/oyad022

Ejemplares similares